Authors
Mohamed Shanavas, Uday Popat, Laura C Michaelis, Veena Fauble, Donal McLornan, Rebecca Klisovic, John Mascarenhas, Roni Tamari, Murat O Arcasoy, James Davies, Usama Gergis, Oluchi C Ukaegbu, Rammurti T Kamble, John M Storring, Navneet S Majhail, Rizwan Romee, Srdan Verstovsek, Antonio Pagliuca, Sumithira Vasu, Brenda Ernst, Eshetu G Atenafu, Ahmad Hanif, Richard Champlin, Paremeswaran Hari, Vikas Gupta
Publication date
2016/3/1
Journal
Biology of Blood and Marrow Transplantation
Volume
22
Issue
3
Pages
432-440
Publisher
Elsevier
Description
The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive patients from participating centers were analyzed, and based on clinical status and response to JAK1/2 inhibitors at the time of HCT, patients were stratified into 5 groups: (1) clinical improvement (n = 23), (2) stable disease (n = 31), (3) new cytopenia/increasing blasts/intolerance (n = 15), (4) progressive disease: splenomegaly (n = 18), and (5) progressive disease: leukemic transformation (LT) (n = 13). Overall survival (OS) at 2 years was 61% (95% confidence interval [CI], 49% to 71%). OS was 91% (95% CI, 69% to 98%) for those who experienced clinical improvement and 32 …
Scholar articles
M Shanavas, U Popat, LC Michaelis, V Fauble… - Biology of Blood and Marrow Transplantation, 2016